Reaction
Immune-Mediated Myositis reporting signals
As of the last recalculation, Immune-Mediated Myositis appears in 2,603 FAERS reports alongside 39 co-occurring drug terms. The strongest observed disproportionality signal is ATORVASTATIN CALCIUM, FILM COATED (PRR 44.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Atorvastatin Calcium, Film Coated | 337 | 44.0 | 44.2 |
| Pembrolizumab | 370 | 32.6 | 32.7 |
| Human Immunoglobulin G | 62 | 24.6 | 24.7 |
| Ipilimumab | 126 | 24.5 | 24.5 |
| Nivolumab | 240 | 21.8 | 21.8 |
| Pitavastatin Calcium | 25 | 19.7 | 19.8 |
| Durvalumab | 47 | 18.8 | 18.8 |
| Atorvastatin Calcium | 348 | 12.8 | 12.8 |
| Rosuvastatin Calcium | 38 | 10.9 | 10.9 |
| Ezetimibe | 95 | 10.5 | 10.5 |
| Atezolizumab | 37 | 7.7 | 7.7 |
| Pemetrexed | 20 | 7.5 | 7.5 |
| Dapagliflozin | 29 | 7.4 | 7.4 |
| Lenvatinib | 29 | 7.1 | 7.1 |
| Metformin Er 500 Mg | 234 | 6.7 | 6.7 |
| Metformin Er 750 Mg | 234 | 6.7 | 6.7 |
| Pemetrexed Disodium | 30 | 6.4 | 6.4 |
| Febuxostat Tablets 40 Mg | 8 | 6.3 | 6.3 |
| Febuxostat Tablets 80 Mg | 8 | 6.3 | 6.3 |
| Simvastatin | 183 | 6.2 | 6.2 |
| Ticagrelor | 24 | 6.1 | 6.1 |
| Rosuvastatin | 147 | 6.0 | 6.0 |
| Inclisiran | 6 | 6.0 | 6.0 |
| Metformin | 245 | 6.0 | 6.0 |
| Carboplatin | 91 | 5.9 | 5.9 |
| Paclitaxel (Aibumin-Bound) | 56 | 5.5 | 5.5 |
| Insulin Glargine-Yfgn | 15 | 5.5 | 5.5 |
| Linagliptin | 12 | 5.3 | 5.3 |
| Sitagliptin And Metformin Hydrochloride | 14 | 5.2 | 5.2 |
| Nebivolol | 10 | 5.0 | 5.0 |
| Paclitaxel | 59 | 4.9 | 4.9 |
| Axitinib | 11 | 4.5 | 4.5 |
| Daratumumab | 20 | 4.0 | 4.0 |
| Icosapent Ethyl | 4 | 3.8 | 3.8 |
| Brinzolamide | 4 | 3.7 | 3.7 |
| Empagliflozin | 30 | 3.6 | 3.6 |
| Alirocumab | 8 | 2.6 | 2.6 |
| Abiraterone | 4 | 2.4 | 2.4 |
| Dulaglutide | 19 | 1.7 | 1.7 |